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As an alternative to targeting human immunodeficiency virus (HIV), we have developed vaccines targeting CCR5, a self-protein
critically involved in HIV replication and pathogenesis. By displaying peptides derived from CCR5 at high density on the surface
of virus-like particles, we can efficiently induce high-titer IgG antibodies against this self-molecule. Here, we investigated
whether prophylactic immunization of rhesus macaques with a particle-based vaccine targeting two regions of macaque CCR5
could prevent or suppress vaginal infection with highly virulent SIVmac251. Twelve macaques were vaccinated with a bacterio-
phage Qß-based vaccine targeting macaque CCR5 (Qß.CCR5). Six control animals were immunized with the Qß platform alone.
All animals immunized with Qß.CCR5 developed high-titer anti-CCR5 antibody responses. Macaques were vaginally challenged
with a high dose of SIVmac251. The mean peak viral RNA levels in the vaccinated groups were 30-fold lower than in the control
group (106.8 versus 108.3 copies/ml plasma). Three of the 12 vaccinated macaques dramatically suppressed simian immunodefi-
ciency virus (SIV) replication: peak viral loads were low (103 to 104 RNA copies/ml), and SIV RNA became undetectable from 6
weeks onward. No viral RNA or DNA could be detected in colon and lymph node biopsy specimens collected 13 months after
challenge. In vivo depletion of CD8 cells failed to induce a viral rebound. However, once anti-CCR5 antibody responses had
waned, the 3 animals became infected after intravaginal and/or intravenous rechallenge. In conclusion, vaccination against
CCR5 was associated with dramatic suppression of virus replication in a subset (25%) of macaques. These data support further
research of vaccination against CCR5 to combat HIV infection.
Human immunodeficiency virus (HIV) sequence diversity andantigenic variation are major and perhaps insurmountable
barriers that hinder the development of vaccines against the virus.
As an alternative strategy to conventional HIV vaccines, we have
developed a vaccine that targets CCR5, a self-molecule that is not
subject to antigenic variation and is critically involved in HIV
acquisition.
During infection, HIV uses chemokine receptors as corecep-
tors in addition to its primary receptor, CD4, to gain entry into
cells (1–3). Although HIV can potentially utilize several corecep-
tors, the viruses isolated from infected individuals early after in-
fection are predominantly CCR5-tropic, indicating a selective ad-
vantage for these viruses during transmission and/or during the
early stages of infection (4, 5). Individuals harboring a homozy-
gous genetic mutation of the CCR5 allele (termed 32) are resis-
tant to HIV infection, and infected heterozygous individuals (who
express lower levels of CCR5) progress more slowly to AIDS (6, 7).
In addition, HIV-1 entry inhibitors targeting CCR5 became an
important component in the arsenal of antiretroviral drugs when,
in 2008, the first small-molecule CCR5 inhibitor, maraviroc
(Pfizer), was approved for clinical use. Maraviroc binds to CCR5
and induces a conformational change to prevent recognition by
the coreceptor binding sites present on the HIV envelope glyco-
protein, gp120. HIV-infected patients receiving maraviroc mono-
therapy have viral loads that are dramatically decreased, often to
undetectable levels (8–10). These data, in addition to the effects of
the 32 mutation on HIV infection, indicate that a reduction in
the availability of functional CCR5 on target cells profoundly di-
minishes both virus acquisition and viral pathogenesis, without
adverse effects on the host.
Unlike viral antigens, in which variants are rapidly selected in
response to host immune pressures, CCR5 is a cellular protein and
is, therefore, genetically stable. We hypothesized that a vaccine
that induced antibodies (Ab) against CCR5— either by inducing
internalization and downregulating its expression on the cell sur-
face or by blocking virus-receptor interactions— could prevent
viral transmission and block viral replication. In support of this
concept, a monoclonal Ab (MAb) against CCR5 has shown some
efficacy in early-stage therapeutic clinical trials (11, 12). However,
because CCR5 is a self-protein, the ability to initiate an antibody
response to the molecule is seemingly limited by the mechanisms
of B cell tolerance, which normally prevent the induction of anti-
body responses to self-molecules. In spite of this, we have shown
that by arraying self-molecules at high density on the surface of
virus-like particles (VLPs), we can completely abrogate these tol-
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erance mechanisms and induce high titer IgG antibodies against
diverse self-antigens (13–18).
Our laboratory has taken advantage of these findings to de-
velop several VLP-based vaccines that elicit anti-CCR5 antibodies,
and other laboratories have used other tolerance-breaking strate-
gies to target CCR5 (19–23). For example, we developed a papil-
lomavirus (PV) VLP-based vaccine targeting the N-terminal ex-
tracellular domain of macaque CCR5 that, in macaques, induces
antibodies that bind to native macaque CCR5 and block virus
infection in vitro (13). Although the antibody responses to immu-
nization with this vaccine were somewhat variable, prophylactic
vaccination of macaques with the CCR5 vaccine reduced viral
loads and time to clearance in pig-tailed macaques infected intra-
venously with a weakly pathogenic CCR5-tropic simian-human
immunodeficiency virus (SHIV), and SHIV clearance was corre-
lated with anti-CCR5 antibody titer and avidity (13). Thus, our
data, and similar results from Misumi and colleagues (19), suggest
that prophylactic vaccination against CCR5 may play a role in
controlling viral replication in a SHIV-macaque model. In con-
trast to these encouraging reports in the SHIV-macaque model, a
DNA vaccine expressing human CCR5 fused to tetanus toxoid
failed to protect macaques from SIVsm challenge (20).
More recently, we have developed bacteriophage particle-
based vaccines that target two extracellular domains of CCR5 that
are involved in HIV binding. These vaccines induce high-titer
anti-CCR5 antibodies in rodents that bind to native macaque
CCR5 and can inhibit simian immunodeficiency virus (SIV) in-
fection in vitro (24). A bivalent vaccine targeting the N-terminal
domain and the second extracellular loop of CCR5 was more ef-
fective at inducing SIV-inhibitory antibodies than each vaccine
separately (24).
In the current study, we investigated whether vaccination
against CCR5 could protect female macaques against intravaginal
(VAG) infection with highly virulent SIVmac251. SIVmac251 was
selected because it uses CCR5 as its main coreceptor, as also dem-
onstrated in vivo by its inhibition by maraviroc (25, 26). We dem-
onstrated that the vaccine was immunogenic and safe and was able
to drastically reduce virus replication in a subset of the animals.
These results support further research on the development of
CCR5-targeting vaccines to reduce HIV transmission.
MATERIALS AND METHODS
Vaccine construct preparation. Qß bacteriophage was prepared by in-
fecting a 500-ml culture of Escherichia coli strain A/ at A600  0.25 with
Qß at a multiplicity of infection of 0.5. After lysis, unlysed cells and insol-
uble cellular debris were removed by centrifugation. Phages were precip-
itated from the supernatant at 4°C overnight after addition of NaCl at 0.5
M and polyethylene glycol (PEG) 8000 at 10%. Precipitate was collected
by centrifugation and then dissolved in TNME (0.1 M NaCl, 10 mM
Tris-HCl, 0.1 mM MgCl2, 0.01 mM EDTA). CsCl was added to achieve a
density of 1.40 g/ml, and the solution was centrifuged to equilibrium at
40,000 rpm using an SW50.1 rotor. The phage band was recovered and
dialyzed against phosphate-buffered saline (PBS; pH 7.4).
A 21-amino-acid peptide (designated EC1) representing the N-termi-
nal 21 amino acids (MDYQVSSPTYDIDYYTSEPC; sulfated at Y10 and
Y14) of macaque CCR5 (mCCR5) was synthesized by American Peptide
(Sunnyvale, CA). A second peptide representing the second extracellular
loop (ECL2) of mCCR5 was synthesized by Celtek Peptides (Nashville,
TN). The ECL2 peptide (DRSQREGLHYTG) is a cyclic peptide spanning
amino acids 168 to 177 of pig-tailed macaque CCR5 in which the Arg and
Thr residues are linked through an Asp-Gly dipeptide spacer (Fig. 1). The
EC1 and ECL2 peptides were directly linked to Qß bacteriophage using a
bifunctional cross-linker (SMPH; Pierce Endogen, IL) as described previ-
ously (24), which allowed us to link the C-terminal cysteine on the pep-
tides to exposed surface lysine residues on the coat protein of Qß. Conju-
gation efficiency was monitored by SDS-PAGE analysis. Each Qß.EC1
particle displayed an average of 90 EC1 peptides, and each Qß.ECL2 par-
ticle displayed an average of 270 ECL2 peptides (data not shown and
reference 24). Equal amounts of the 2 constructs (Qß.EC1 and Qß.ECL2)
were mixed to formulate the Qß.CCR5 vaccine. Wild-type Qß was used as
a placebo vaccine construct.
Animals. All 18 animals were primiparous (n  1) or multiparous
(n  17) adult female rhesus macaques (Macaca mulatta), with an age
range of 10 to 14 years, and were housed at the California National Pri-
mate Research Center (CNPRC) in accordance with American Associa-
tion for Accreditation of Laboratory Animal Care standards. We strictly
adhered to the Guide for the Care and Use of Laboratory Animals prepared
by the Committee on Care and Use of Laboratory Animals of the Institute
of Laboratory Resources, National Resource Council (27). The study was
approved by the Institutional Animal Care and Use Committee of the
University of California Davis. Of the 18 animals, 15 were Indian-origin
rhesus macaques. The remaining 3 animals (29741, 31380, and 32214)
were one-fourth Chinese origin and three-fourth Indian origin and were
assigned as one animal per study group.
Animal immunizations. The CCR5 vaccine constructs were adminis-
tered by the intramuscular (IM) or intravaginal (VAG) route. For the
intramuscular immunizations, 0.5 ml of Qß.CCR5 vaccine (consisting of
25 g each of Qß.EC1 and Qß.ECL2 constructs in PBS– 0.25 ml of incom-
plete Freund adjuvant [Sigma-Aldrich, St. Louis, MO]) was injected into
the right and left quadriceps muscles in an alternating manner. The intra-
vaginal immunizations consisted of 2 steps: 1 ml of 3% CMC (carboxym-
ethylcellulose; an inert gel) plus 4% nonoxynol-9 (N-9) (Spectrum, Gar-
dena, CA) was slowly administered to the vaginal lumen, followed 6 h later
with the actual immunization of 50 g each of the Qß.EC1 and Qß.ECL2
constructs in 100 l via the use of an aerosolizing high-pressure syringe
(model FMJ-250; Penn-Century Inc., Wyndmoor, PA). A control group
of six macaques received four intramuscular inoculations of 50 g of
wild-type Qß (with 0.25 ml incomplete Freund adjuvant for a total vol-
ume of 0.5 ml per immunization).
SIV inoculations. To test the efficacy of the vaccine regimens, we used
a previously established high-dose intravaginal inoculation regimen, de-
signed to ensure a nearly 100% infection rate among unimmunized con-
trol animals (28, 29). Twice in a single day (with the two occasions sepa-
rated by a 4-h interval), 1 ml of undiluted SIVmac251 was administered
atraumatically and slowly via a 1-ml needleless syringe into the vagina.
The SIVmac251 stock (reference number 6/04), which was propagated on
rhesus peripheral blood mononuclear cells [PBMC]), contained approx-
imately 109 SIV RNA particles per ml, or 105 50% tissue culture infective
doses (TCID50) per ml (30). No Depo-Provera treatment was used, and all
animals were inoculated on the same day without regard for the stage of
the menstrual cycle.
Collection and processing of blood and tissue specimens. When nec-
essary, animals were immobilized with ketamine HCl (Parke-Davis, Mor-
ris Plains, New Jersey) injected intramuscularly at 10 mg/kg of body
weight. Blood samples were collected regularly for monitoring viral and
immunologic parameters as described previously (31). Complete blood
counts (CBC) were performed on EDTA-anticoagulated blood samples.
Samples were analyzed using a Pentra 60C analyzer (ABX Diagnostics);
differential cell counts were determined manually.
To collect cervical secretions, a speculum was inserted into the vagina
and two Weck-Cel sponges (Eye Spears; Beaver-Visitic, Waltham, MA)
were placed sequentially in the endocervical canal for 1 min each and then
carefully removed and placed in tubes and frozen.
Lymphoid tissues collected at euthanasia were processed to obtain cell
suspensions by dissecting them with scalpels in RPMI 1640 (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Gemini
BioProducts, Calabasas, CA) (complete RPMI) and passing the cell ho-
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mogenate through a cell strainer (Fisher, Pittsburgh, PA). Mononuclear
cells were isolated from the splenic cell suspensions and the blood by
density gradient centrifugation with Lymphocyte Separation Medium
from MP Biomedicals (Aurora, OH), followed by two washes with RPMI
1640.
For some animals, biopsy specimens of axillary lymph node and tra-
verse colon were collected and processed to obtain mononuclear cell sus-
pensions according to previously described methods, including collage-
nase digestion of the colon samples (32, 33).
Determination of host genetics. Major histocompatibility complex
(MHC) typing for 9 class I alleles (Mamu-A*01, Mamu-A*02, Mamu-
A*08, Mamu-A*11, Mamu-B*01, Mamu-B*03, Mamu-B*04, Mamu-
B*08, and Mamu-B*17) was performed using methods previously de-
scribed (34, 35). TRIM5 genotyping was not performed, because a
previous study demonstrated that mucosal SIVmac251 infection is not
susceptible to TRIM5 restriction (36).
Quantitation of SIV RNA and DNA. SIV RNA levels in plasma sam-
ples were tested by a real-time reverse transcription-PCR (RT-PCR) assay
for SIV gag, as previously described in detail (37); this assay has a cutoff
value of 30 copies for a 0.5-ml plasma sample. To determine cell-associ-
ated viral RNA and DNA levels, cell pellets of approximately 2 million
PBMC or lymphoid cells isolated from lymphoid tissues (axillary lymph
node or colon biopsy specimens) were snap frozen and stored at 70°C.
The cell pellets were subsequently tested for SIV gag RNA and DNA and
CCR5 DNA (as a reference for cell equivalents) according to methods
described previously (38). Assays were routinely run in duplicate. For
these assays, variability on replicate samples run on separate days was on
the order of a 25% to 30% coefficient of variation (CV). Based on samples
from known uninfected and unexposed animals, the false-positive rate
was extremely low (	0.2%) and was always resolved by duplicate testing.
The plasma viral RNA set point was defined as the mean viral RNA
level from week 6 after SIV infection to week 20 or at the time of eutha-
nasia (if earlier).
Viral envelope sequence analysis using single-genome amplifica-
tion. Plasma was obtained from each animal at 7 to 21 days postchallenge,
and viral RNA was extracted using a QIAamp Viral RNA Minikit (Qia-
gen). RNA was eluted and immediately subjected to cDNA synthesis. Re-
verse transcription of RNA to single-stranded cDNA was performed using
SuperScript III reverse transcription according to the manufacturer’s rec-
ommendations (Invitrogen). In brief, a cDNA reaction mixture consist-
ing of 1
 RT buffer, 0.5 mM each deoxynucleoside triphosphate, 5
mM dithiothreitol, 2 U/ml RNaseOUT (RNase inhibitor), 10 U/ml of
Superscript III reverse transcriptase, and 0.25 mM antisense primer
SIVmacV4R1 (5=-TTT ACW ATT TGY CTW ATT CT-3= [where Y is C or
T and W is A or T]) was incubated at 50°C for 60 min and at 55°C for 60
min and was then heat inactivated at 70°C for 15 min followed by treat-
ment with 1 U of RNase H at 37°C for 20 min. The newly synthesized
cDNA was used immediately.
The V1-to-V4 loop of the env gene was amplified and sequenced using
a limiting dilution PCR where only a single genome is amplified (SGA) per
reaction. PCR was performed with 1
 PCR buffer, 2 mM MgCl2, 0.2 mM
each deoxynucleoside triphosphate, 0.2 M each primer, and 0.025 U/l
Platinum Taq polymerase (Invitrogen) in a 20-l reaction mixture.
First-round PCR was performed with sense primer SIVmacV1F1 (5=-TGT
GCA ACC AAG AAT AGG GAT ACT TG-3=) and antisense primer
SIVmacV4R1 under the following conditions: 1 cycle of 94°C for 2 min
and 35 cycles of 94°C for 15 s, 55°C for 30 s, and 72°C for 4 min, followed
by a final extension of 72°C for 10 min. Next, 1 l from the first-round
PCR product was added to a second-round PCR that included the sense
primer SIVEnvF2 (5=-CAG TCA CAG AAC AGG CAA TAG AGG-3=) and
FIG 1 Preparation of two CCR5 vaccine constructs. A linear peptide representing the N terminus (EC1) and a cyclic peptide representing the undecapeptidyl
arch of the second extracellular loop (ECL2) of macaque CCR5 (A), representing two different regions that interact with HIV gp120 during infection, were
synthesized and then conjugated at high density to Qß bacteriophage using the bifunctional cross-linker SMPH to obtain Qß.EC1 and Qß.ECL2 particles,
respectively (B). The image of Qß bacteriophage was generated using RasMol and a structure of Qß from the Brookhaven protein database.
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antisense primer SIVEnvR2 (5=-TAR AAR AAT TCT CCT CCA CA-3=)
performed under the same conditions used for first-round PCR but with
a total of 45 cycles. Correctly sized amplicons were identified by agarose
gel electrophoresis and directly sequenced with second-round PCR prim-
ers using BigDye Terminator technology. To confirm PCR amplification
from a single template, chromatograms were manually examined for mul-
tiple peaks, indicative of the presence of amplicons resulting from PCR-
generated recombination events, Taq polymerase errors, or multiple-vari-
ant templates. All 92 sequences were deposited in GenBank under
accession numbers KF542561 to KF542652).
Virus isolation. PBMC or lymph node mononuclear cells were
cocultured with CEMx174 cells in T25 flasks, and subsequent p27 core
antigen measurement was performed according to methods previously
described (39).
In vivo CD8 cell depletion. CD8 cells were depleted in three ma-
caques through a single administration of anti-CD8 monoclonal antibody
M-T807R1, given at a dose of 50 mg/kg via slow intravenous infusion
according to the manufacturer’s instructions (http://www.nhpreagents
.org/NHP/default.aspx).
Phenotyping of lymphocyte populations. Multiparameter flow cyto-
metric analysis was performed to characterize lymphocyte populations in
PBMC and tissue cell suspensions. All antibodies were from BD Biosci-
ences (San Jose, CA) unless otherwise stated. Cell suspensions were
stained with peridinin chlorophyll protein (PerCP)-conjugated anti-hu-
man CD8 (clone SK1; Becton, Dickinson Immunocytometry Inc., San
Jose, CA), fluorescein isothiocyanate (FITC)-conjugated anti-human
CD3 (clone SP34; Pharmingen), phycoerythrin (PE)-conjugated anti-hu-
man CD4 (clone M-T477; Pharmingen), and allophycocyanin (APC)-
conjugated anti-human CD20 (clone L27; Becton, Dickinson) for 4-color
flow cytometry and analyzed on a FACSCalibur flow cytometer, as de-
scribed previously (31). CD4 T lymphocytes, CD8 T lymphocytes, NK
cells, and B cells were defined as CD4 CD3, CD8 CD3, CD8
CD3, and CD20 CD3 lymphocytes, respectively. During the in vivo
CD8 cell depletion experiment, as suggested elsewhere (http://www
.nhpreagents.org/NHP/default.aspx), the anti-CD8 antibody was re-
placed by the DK25 clone (Dako, Carpinteria, CA) conjugated to PE (and
combined with anti-CD3-PerCP, anti-CD4-FITC, and anti-CD20-APC).
A separate aliquot of blood was stained with anti-CD3-PerCP (clone
SP34-2), anti-CD4-APC (clone L200), anti-CD195 (CCR5)-PE (clone
3A9), and anti-CD95-FITC (clone DX2). The number of anti-CCR5-PE
antibodies bound per CD4 CD3 T cell was measured via the use of
QuantiBRITE PE beads according to the manufacturer’s instructions.
In separate tubes, T cell subpopulations of CD3 (clone SP34-2) and
CD4 (L200) or CD8 (SK1) T cells were further defined by markers for
memory [CD45RA (5H9) and CCR7 (3D12)], activation [Ki-67 (B56)
and CD69 (FN-50)], and apoptosis [PD-1 (J105; eBioscience), Bcl-2 (Bcl-
2/100), and caspase 3 (C92-605)]. In addition, blood or tissue single-cell
suspensions were added to round-bottom tubes and treated with 0.5 g
purified anti-CD28 and anti-CD49d (BD Biosciences) in 1 ml supple-
mented RPMI medium plus (ii) no stimulant, (ii) 10 g SIVmac239 p27
Gag peptide pool (peptides 5243 to 5299; AIDS Research and Reference
Reagent Program no. 6204), (iii) 10 g SIVmac239 Env peptide pool
(peptides 6708 to 6719; AIDS Research and Reference Reagent Program
no. 6883), or (iv) phorbol myristate acetate (PMA; 5 ng/ml)-ionomycin
(500 ng/ml) (Sigma, St. Louis, MO) as a positive control. Stimulated cells
were incubated at 37°C and 5% CO2 for 1 h and then treated with 1

brefeldin A (eBioscience) and incubated for an additional 5 h. Cells were
then washed and stained using a fixable Live/Dead discriminator (Invit-
rogen) and antibodies against intracellular cytokines interleukin-2 (IL-2)
(MQ1-17H12), tumor necrosis factor alpha (TNF-) (MAb11), gamma
interferon (IFN-) (B27), IL-17A (64CAP17; eBioscience), and granzyme
B (B11). Cells were fixed in 1% paraformaldehyde and stored in the dark
at 4°C until analysis. Samples were acquired on a LSR II instrument and
analyzed using FlowJo software with Boolean gating (TreeStar, Ashland,
OR). Staining panels were evaluated using fluorescence-minus-one
(FMO) controls. Antigen-specific T cell responses were represented as the
percentage of positive cells within the CD4 or CD8 T cell populations
after subtraction of background responses in unstimulated cultures.
Detection of anti-CCR5 antibody responses. Sera were tested for an-
tibodies specific for the CCR5-EC1 and ECL2 peptides and Q bacterio-
phage VLPs by enzyme-linked immunosorbent assay (ELISA). Briefly,
Immulon II ELISA plates (Dynex Technologies, Chantilly, VA) were
coated overnight at 4°C with 0.5 g of either EC1 or ECL2 peptide (con-
jugated to streptavidin using the cross-linker SMPH; Thermo Scientific,
Rockford, IL) or 0.5 g Q VLPs per well. Wells were then blocked with
50 l of PBS– 0.5% milk (wt/vol) per well for 2 h at room temperature. An
initial 1:40 dilution of serum was serially diluted 4-fold and applied to
wells for 2.5 h at room temperature. All dilutions were done in 0.5% milk
(wt/vol)–PBS unless otherwise noted. Reactivity to target peptides was
determined by using horseradish peroxidase (HRP)-labeled goat anti-
monkey IgG (Fitzgerald Industries, Acton, MA) at a dilution of 1:4,000,
and the reaction mixtures were incubated for 1 h at room temperature.
Upon development, the optical density at 405 nm (OD405) was deter-
mined using a Thermo Max microplate reader (ThermoLab Systems;
Fisher Scientific, Pittsburgh, PA). Absorbance values greater than twice
the background were considered positive.
Detection of SIV-specific antibody responses. SIV-specific immuno-
globulin G (IgG) in plasma samples was detected by ELISA as described
previously (40). Briefly, Costar enzyme immunoassay-radioimmunoas-
say (EIA/RIA) plates (Fisher Scientific, Santa Clara, CA) were coated with
purified whole SIVmac251, and serial 4-fold dilutions of plasma or serum,
starting from a 1:100 dilution, were tested. Titers were determined as the
highest dilution with an OD above the cutoff value.
Viral inhibition assay. The viral inhibition assay was performed via a
modification of a neutralization assay that measures a reduction in lucif-
erase reporter gene expression after a single round of infection in TZM-bl
cells (which express human CCR5) as described previously (41, 42).
TZM-bl cells were obtained from the NIH AIDS Research and Reference
Reagent Program, as contributed by John Kappes and Xiaoyun Wu.
Briefly, freshly trypsinized cells (10,000 cells in 100 l of growth medium
containing 75 g/ml DEAE dextran) were preincubated for 1 h at 37°C in
96-well flat-bottom culture plates with serial 3-fold dilutions of plasma
prior to addition of virus (150,000 relative luminescence units [RLU]
equivalents) in duplicate, in a total volume of 250 l. Samples were tested
against the very neutralization-sensitive T cell line-adapted (TCLA)-SIV-
mac251 stock (grown in H9 cells) and two neutralization-resistant virus
stocks, SIVmac251CS (grown in human PBMC) and SIVmac239CS
(grown in 293 T cells). One set of control wells received cells plus virus
(virus control), another set received cells only (background control), and
a third set received murine leukemia virus (MLV)-pseudotyped virus sim-
ian virus amphotropic MLV (SVA-MLV) (grown in 293T cells) as a con-
trol for nonspecific viral inhibition. After a 48-h incubation, cells were
lysed using a Britelite luminescence reporter gene assay system
(PerkinElmer Life Sciences) and three-fourths of the lysate was trans-
ferred to 96-well black solid plates (Costar) for measurements of lumines-
cence. Neutralization titers were determined as the dilution at which RLU
were reduced by 50% compared to virus control wells after subtraction of
background RLU.
Criteria for euthanasia and necropsy. Euthanasia of animals with
simian AIDS was determined by established criteria of one or more of the
following clinical observations indicative of a severe life-threatening situ-
ation: weight loss of 15% in 2 weeks or 25% over any time course;
chronic diarrhea or another opportunistic infection(s) unresponsive to
treatment; inability to maintain body heat or fluids without supplemen-
tation; obtundation; neurologic deficits; and persistent, marked hemato-
logic abnormalities, including anemia (	20%), thrombocytopenia with
petechiae or ecchymosis, and hypoproteinemia with edema. A complete
necropsy with collection of formalin-fixed tissues was performed.
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Statistical analysis. Statistical analyses were performed with Prism 5
for Mac and Instat 3 (GraphPad Software Inc., San Diego, CA). A value of
P of 	0.05 was considered statistically significant.
Nucleotide sequence accession numbers. All 92 sequences deter-
mined in this work were deposited in GenBank under accession numbers
KF542561 to KF542652).
RESULTS
Overview of experimental design. Eighteen adult female ma-
caques were divided into three groups of 6 animals each. Two of
these groups were immunized with Qß.CCR5, a vaccine targeting
two extracellular domains of the CCR5 receptor that were selected
because of their role in HIV binding to CCR5 (43, 44) (Fig. 1). One
of these targets was a 21-amino-acid peptide that corresponds to
the amino terminus of macaque CCR5. The tyrosines at positions
10 and 14 of the peptide were sulfated to reflect the fact that sul-
fation of these residues in native CCR5 is thought to be important
in HIV binding (45). The second antigen was a cyclic peptide
spanning amino acids 168 to 177 of the second extracellular loop
of macaque CCR5 in which the Arg and Thr residues are linked
through an Asp-Gly dipeptide spacer. This peptide was originally
identified as an immunogen capable of inducing anti-CCR5 anti-
bodies by Misumi and colleagues presumably because it mimics
the native conformation of the epitope (46). Both peptides are
highly conserved between macaques and humans; the N-terminal
sequence contains only two amino acid differences (at residues 9
and 13), and the cyclic peptide contains one (at residue 171).
Peptides were individually conjugated to Qß VLPs and then com-
bined to formulate the Qß-CCR5 vaccine.
Group 1 (IM) received Qß.CCR5 as 4 intramuscular immuni-
zations at weeks 24, 20, 16, and 2 (relative to SIV inocu-
lation), and the 2nd group (IM/VAG) first received an intramus-
cular prime immunization with Qß-CCR5 at week 24, followed
by three vaginal booster immunizations at weeks 20, 16, and
2 (Fig. 2). As outlined in Materials and Methods, each vaginal
immunization was performed using a high-pressure microsprayer
syringe at 6 h after chemical disruption of vaginal epithelia with
nonoxynol-9. The last group (“placebo”) received four intramus-
cular inoculations with unmodified Qß. At time zero, all animals
received a high-dose intravaginal challenge of SIVmac251 (two
doses of 105 TCID administered 4 h apart), after which the animals
were monitored regularly for infection status and disease progres-
sion.
Observations during the immunization period prior to SIV
challenge. The Qß.CCR5 vaccine was immunogenic, as high-titer
IgG responses to both domains of CCR5 were detected in plasma
of all 12 of the macaques that received Qß.CCR5 immunizations.
Compared with that of the responses to Qß.CCR5 immunization
in inbred mice (24), the magnitude of the antibody responses was
somewhat more variable in the outbred macaques. Titers of anti-
body against the ECL2 peptide were slightly higher than those
against the EC1 peptide (Fig. 3), likely reflecting the fact that the
ECL2 peptide was displayed on Qß particles at a higher density.
Intravaginal boosting successfully increased antibody levels in the
serum; between weeks 20 and 10, anti-EC1 and anti-ECL2
antibody levels increased 6.5-fold and 17-fold, respectively (P 	
0.05), which is similar to the boosting we previously observed
upon intravaginal vaccination of mice (47). However, macaques
that received four intramuscular injections developed higher an-
tibody titers than those seen with the group that received intra-
vaginal boosts (Fig. 3). Nevertheless, all 12 macaques had peak
anti-CCR5 endpoint dilution titers of greater than 103 (EC1) and
104 (ECL2). These antibody titers remained relatively stable
throughout the immunization period. At the time of SIV chal-
lenge (2 weeks after the last immunization), antibody titers in
individual macaques were no lower than 1 4-fold dilution from
each animal’s respective peak antibody titer. Although we tried to
collect cervical secretions using Weck-Cel sponges, the protein
yield in the samples was too low for further antibody analysis.
There were no detectable adverse effects of the anti-CCR5 im-
munizations, based on clinical observations, CBC data, and values
(percentages and cell counts per l) of the major lymphocyte sub-
sets in peripheral blood (CD4 and CD8 T lymphocytes, NK
cells, and B lymphocytes; data not shown). Flow cytometry tech-
niques were used to determine if the development of plasma anti-
CCR5 antibodies reduced CCR5 expression on CD4 T lympho-
cytes. There was no difference between the animal groups in the
numbers of CCR5 molecules on the surface of CD4 T lympho-
cytes; the estimated average numbers of anti-CCR5-PE antibodies
bound per cell ranged from 738 to 4,883 (Fig. 4A), which is similar
to results previously described for human CD4 T cells (48). In
addition, during the immunization period prior to SIV inocula-
tion, there was no difference between the immunized groups and
the placebo group in percentages or absolute numbers of CCR5
CD4 T lymphocytes and CD4 T lymphocytes or in the CD4/
CD8 T cell ratio in peripheral blood (Fig. 4B to D).
Plasma collected at time zero (i.e., the time of virus inocula-
tion) was tested in an in vitro viral inhibition assay using TZM-bl
cells. No antiviral activity against the control virus SVA-MLV or
against SIVmac239CS was detected (all titers 	 1:20). Sporadic
but very low inhibitory activity (titers 	 70) was detected against
SIVmac251/CS and SIVmac251-TCLA; however, some samples
from control animals also had low inhibitory activity, and there
was no correlation with vaccine groups and outcome after SIV
challenge (data not shown).
FIG 2 Experimental design of animal studies. Eighteen animals were divided
in groups of 6 animals each. Group 1 (IM) received 4 intramuscular immuni-
zations with Qß-CCR5 at weeks 24, 20, 16, and 2. Group 2 (IM/VAG)
received an intramuscular prime immunization with Qß-CCR5 at week 24
followed by vaginal boosts with vaginal booster immunizations at weeks 20,
16, and 2. Group 3 (placebo) received 4 intramuscular immunizations
with the control vector Qß. At time zero, all animals received a high-dose
intravaginal challenge of SIVmac251 (2
 105 TCID). Three animals (1 of
group 1 and two of group 2) which had transient viremia were depleted of
CD8 cells at 58 weeks of infection and rechallenged intravaginally at week 72
and, if still not viremic, intravenously at week 78.
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As expected, because the Qß.CCR5 and Qß vaccine constructs
did not contain any SIV sequences, no SIV-specific antibody re-
sponses were detected in any of the animals (all titers 	 1:100 by
ELISA; data not shown) prior to the SIV challenge.
Virologic and clinical outcome after vaginal SIVmac251
challenge. Following the high-dose SIVmac251 challenge, all an-
imals became infected based on detection of viral RNA in plasma
during the first 4 weeks after inoculation. Overall, the mean peak
viral RNA levels in the 12 vaccinated animals were approximately
30-fold lower than in the control animals (106.8 versus 108.3 copies
per ml plasma; P  0.08, one-tailed t test). However, two distinct
patterns emerged: 15 animals (including all 6 controls) demon-
strated a typical course of SIVmac251 infection with persistent
viremia, while 3 immunized animals had an atypical course of
infection characterized by transient viremia (Fig. 5).
All 6 control animals, 5 of the 6 animals of the CCR5 IM group,
and 4 of the 6 animals of the CCR5 IM-IVAG group developed
high peak viremia (107 SIV RNA copies per ml plasma) within
the first 3 weeks after inoculation, followed by persistent viremia
(Fig. 5). While the viral RNA set points for the control animals
were all 106 RNA copies/ml, the CCR5 IM group had one animal
with a viral set point of 104 copies/ml (animal 31380; Fig. 5C).
Viral RNA levels were predictive of disease-free survival. Of these
15 persistently viremic animals, the 7 animals with the highest
level of viremia (107 RNA copies/ml) showed a rapid decline in
CCR5 and CD4 T lymphocyte numbers and CD4/CD8 T
cell ratio (Fig. 4B to D) and met the clinical criteria for euthanasia
within 18 weeks of infection. These 7 rapid progressors mounted
low anti-SIV antibody responses (peak titers  1,600 by ELISA),
which is consistent with previous observations of rapid progres-
sors in this animal model (49, 50). The remaining 8 persistently
viremic animals had generally lower virus levels (Fig. 5), associ-
ated with a slower depletion of CD4 T lymphocytes (Fig. 4) and
higher SIV-specific antibody responses (peak titers  25,600; data
not shown). Five of these 8 animals met the criteria for euthanasia
at between 25 and 50 weeks of infection, while the remaining 3
animals (29741, 32571, and 31380) were clinically stable when
euthanized at the experimental endpoint of 1 year after SIV infec-
tion (Fig. 5).
The remaining 3 animals (32787, 30285, and 32214), which all
belonged to the two CCR5-immunized groups and whose the an-
ti-CCR5 antibody titers were in the upper range within their re-
spective groups, had a remarkably different outcome of infection.
All 3 animals had detectable plasma viral RNA at 4 consecutive
time points (weeks 1, 2, 3, and 4 postinoculation), with peak levels
of 740 to 21,000 RNA copies per ml (Fig. 5). However, from week
6 onward, all plasma samples tested negative for SIV RNA (i.e., the
results were below the detection limit of 10 to 30 copies per ml,
depending on specimen volume). For these 3 animals, no infec-
tious virus could be isolated from 5 million PBMC at the time
point of peak viral RNA levels. Despite this transient detection of
RNA in plasma, these 3 animals did not seroconvert, as no SIV-
specific IgG could be detected in any plasma samples, including all
early time points (all titers 	 100 by ELISA; data not shown).
These 3 animals maintained normal CD4 and CD8 T cell
counts, including CCR5 CD4 T cell counts (Fig. 4).
In an attempt to explain the different disease courses, we eval-
uated viral and host genetics. Sequence analysis of the V1-to-V4
loop of the env gene was performed on plasma collected at week 2
(for the persistently viremic animals) or at week 1 or 3 (i.e., at the
respective times of peak viremia) for the animals with transient
viremia. Very little total diversity was detected, and the sequence
data were consistent with those reported previously for this par-
ticular SIVmac251 stock (51). There were no obvious differences
between the three experimental groups in early viral envelope se-
quences and no differences between the 7 rapid progressors, 8
normal progressors, and 3 animals with transient viremia (data
not shown; GenBank accession numbers KF542561 to KF542652).
Animals were typed for MHC class I alleles that in some studies
correlated with lower viremia (Mamu-A*01, Mamu-B*08, and
Mamu-B*17) or higher viremia (Mamu-B*01) of some, but not
all, SIV isolates, particularly SIVmac239 (35, 52–54). In this study,
similar to previous studies conducted with our SIVmac251 stocks
(31, 32), no correlation was observed between these MHC class I
FIG 3 Anti-CCR5 responses in macaques immunized with Q.CCR5. EC1 and ECL2 peptide-specific antibody titers (expressed as endpoint dilution titers) were
measured by ELISA in plasma from macaques immunized by the routes indicated. Macaques were immunized at weeks 24, 20, 16, and 2 and were
challenged at week 0 (vertical line). Asterisks indicate the macaques that controlled SIV infection.
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alleles and disease progression; in particular, the control group
had the highest frequency of so-called “protective” alleles, while
two of the three animals that had transient viremia had no protec-
tive alleles (Table 1).
In the absence of Q.CCR5 booster immunizations, antibody
titers in plasma against the EC1 and ECL2 peptides declined after
SIV challenge. At 55 weeks after SIV challenge, for the 3 animals
with transient viremia, the antibody titers in animals 30285 and
32214 had declined to below the limit of detection (	40), while
anti-EC1 and anti-ECL2 titers in animal 32787 were 2,560 and
640, respectively (data not shown).
Biopsy collection, CD8 cell depletion, and rechallenge of
the 3 animals with transient viremia. To look for viral reservoirs
in the 3 animals with transient plasma viremia, PBMC and mono-
nuclear cells isolated from axillary lymph node and colon biopsy
specimens collected at week 56 were tested by PCR for cell-asso-
ciated SIV RNA and DNA. All samples were negative (results were
below the detection limit of 1 to 2 copies of SIV RNA or DNA per
FIG 4 Immunological markers in macaques immunized with Q.CCR5 and subsequently challenged with virulent SIVmac251. Animals received 4 immuni-
zations (dotted arrows) with placebo or Qß-CCR5 and were then inoculated intravaginally with SIVmac251 (solid arrows). Flow cytometry techniques were used
on whole blood to measure the density of CCR5 molecules on the surface of CD4 T cells (A), the number of CCR5 CD4 CD3 lymphocytes (B), the number
of CD4 CD3 lymphocytes (C), and the CD4/CD8 T cell ratio (D) in peripheral blood.
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FIG 5 Plasma SIV RNA levels after vaginal SIVmac251 inoculation. Panel A shows the means (after log transformation) of viral RNA levels in plasma of the 3
experimental groups. Panels B through D show the results for the individual animals within each group. At time zero, all animals were inoculated intravaginally
with SIVmac251. Three animals (32787, 30285, and 32214) received another intravaginal inoculation at 72 weeks, and the 2 protected animals (32787 and 32214)
then received an intravenous inoculation at 78 weeks. In panels C and D, the anti-CCR5 IgG titers in plasma at the time of SIV challenge are shown. Survival is
indicated by the time when animals were euthanized because they met the established clinical criteria;  indicates that the animals were euthanized at the
indicated time point without meeting these clinical criteria. The time points of CD8 depletion and SIV rechallenges on 3 animals that controlled initial infection
are indicated.
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100,000 cellular equivalents). In addition, for all 3 animals, no
virus could be isolated from 4 to 10 million PBMC and axillary
lymph node mononuclear cells using coculture experiments.
Thus, despite the initial viremia, there was no detectable evidence
of infection afterward based on the viral and immunological
markers assessed in this study.
To further substantiate that conclusion, and to determine if the
atypical course of infection in the 3 animals with transient viremia
was due to strong cell-mediated antiviral immune responses, an in
vivo CD8 cell depletion experiment was performed. At 58 weeks
after SIV inoculation, the three animals were administered an an-
ti-CD8 antibody that in previous studies induced a transient in-
crease in viremia in SIV-infected animals (31, 55, 56). Following a
single infusion of anti-CD8 antibody M-T807R1, the CD3 CD8
T cell and CD3 CD8 NK cell counts in peripheral blood were
undetectable or very low (5 per l) for 3, 8, and 9 weeks in
animals 32787, 30285, and 32214, respectively (Fig. 6). Through-
out the close observation period of 14 weeks after CD8 cell de-
pletion, 14 blood samples were collected from each animal at fre-
quent intervals (i.e., twice a week for the first 2 weeks, then weekly
for the next 6 weeks, and then biweekly for the following 6 weeks).
None of the plasma samples had detectable viral RNA levels (all
values were below the detection limit of 10 RNA copies/ml). In
addition, no SIV-specific antibodies could be detected (all titers 	
1:100). In conclusion, the CD8 cell depletion experiment failed
to induce viremia and seroconversion.
At 14 weeks after the CD8 cell depletion experiment (i.e.,
at 72 weeks after the first vaginal SIV inoculations), all three
animals were rechallenged using exactly the same regimen,
namely, two intravaginal administrations (administered 4 h
apart in a single day) of 1 ml containing 105 TCID50 of SIV-
mac251. This time, animal 30285 became highly viremic; al-
though we monitored this animal for only 6 weeks after rechal-
lenge, the available evidence indicated features of a rapid
progressor (persistently high viremia  107 copies/ml [Fig.
5D]; low SIV-specific IgG titer of 1:100 at week 6). This animal
had also low SIV-specific cell-mediated immune responses in
PBMC (1.2% of CD4 cells and CD8 cells expressed at least
TABLE 1 Typing of MHC class I alleles
Group Animal no.
Presence or absence of allele or % CNPRC frequencya
MHC scoreb Survival (wks)cA01 A02 A08 A11 B01 B03 B04 B08 B17
1 (IM) 29469          0 26
30640          0 17
30784          1 25
31380          0 52
31393          0 50
32787*          0 86
2 (IM/VAG) 29709          0 18
30285*          0 75
30793          0 26
31512          1 14
32060          1 11
32214*          1 86
3 (control) 29741          1 52
29806          0 34
31336          1 10
31621          0 16
32499          2 14
32571          1 52
CNPRC frequency 18.8 13.8 13.0 9.1 29.9 1.2 1.5 7.1 11.2
a , present; , absent. Numerical data represent frequencies of alleles in the general rhesus macaque colony of the California National Primate Research Center.
b The MHC scores were calculated by adding one point for each protective allele (Mamu-A*01, Mamu-B*08, and Mamu-B*17) and subtracting a point for Mamu-B*01, which has
been associated with higher viral levels; other alleles were given a zero score (35, 52–54). There were no statistically significant differences in the frequencies of the individual alleles
or MHC scores between the groups (P values  0.5). The mean MHC scores for groups 1 (IM), 2 (IM/VAG), and 3 (control) were 0.17, 0.17, and 0.5, respectively.
c Survival is indicated by the time (in weeks) when animals met established clinical criteria for euthanasia; the  sign indicates animals subjected to euthanasia at this time prior to
meeting the clinical criteria.
FIG 6 CD8 cell depletion of three aviremic animals. At 58 weeks after the initial
intravaginal SIV inoculation, the three aviremic animals were given a single infu-
sion of anti-CD8 antibody M-T807R1. The absolute cell counts of CD3 CD8 T
cells and CD3 CD8 NK cells in peripheral blood are presented.
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one cytokine after in vitro stimulation with SIV Gag or Env
peptides; data not shown). In contrast, the other 2 animals
(32214 and 32787) maintained undetectable plasma viral RNA
levels (	10 copies/ml), with the exception that the plasma col-
lected from animal 32214 2 weeks after intravaginal rechallenge
had 14 SIV RNA copies per ml. Neither of these animals devel-
oped detectable SIV-specific antibodies or SIV-specific cell-
mediated immune responses (as measured by flow cytometry
with intracellular cytokine staining; data not shown).
Because the resistance of these animals to the repeated mucosal
challenges was remarkable, we investigated whether these 2 ani-
mals had any inherent genetically defined resistance to infection
by exposing them to the most stringent route of exposure, namely,
intravenous inoculation. Therefore, at 6 weeks after the vaginal
SIV rechallenge (i.e., at 78 weeks after the initial vaginal chal-
lenge), the same high dose of SIVmac251 (1 ml of 105 TCID50) was
administered to both animals by the intravenous route. Both an-
imals became persistently infected (peak viremia  107 RNA cop-
ies/ml plasma) and seroconverted by week 4 (SIV-specific IgG
titer of 1:1,600). At week 3, no SIV-specific cell-mediated immune
responses were detectable in PBMC of either animal. However,
animal 32214, which experienced an approximately 2-log reduc-
tion in plasma SIV RNA levels following peak viremia (Fig. 5D),
had high levels of SIV-specific cell-mediated immune responses in
both CD4 and CD8 lymphocyte populations at the time of
euthanasia (i.e., 7 weeks after intravenous challenge), when 25%
of CD4 T cells and CD8 T cells secreted at least one cytokine
upon in vitro stimulation with SIV Gag or Env peptides (data not
shown). In contrast, animal 32787, which maintained higher
plasma viremia, had very low SIV-specific immune responses by
the time of euthanasia at week 7 of infection (	0.12% of CD4
cells and 0.2% of CD8 cells expressing at least one cytokine;
data not shown).
DISCUSSION
The current pilot study was aimed at exploring—in a preclinical
animal model with highly virulent challenge virus—the feasibility
of an anti-HIV vaccine that, instead of targeting viral proteins,
would exert antiviral activity through the induction of antibodies
to the CCR5 coreceptor.
Considering that any vaccine that induces an antibody re-
sponse to a self-protein engenders safety concerns that generate
substantial regulatory and public perception hurdles, it was en-
couraging that immunization with Qß.CCR5 elicited high-titer
antibody responses in macaques without overt adverse effects. Al-
though the primary goal of the current nonhuman primate study
was the evaluation of immunogenicity and efficacy, the available
data indicate that the CCR5 vaccine was well tolerated, as no safety
concerns were raised during the 24-week immunization period.
Although the safety assessment was limited in duration because of
the subsequent SIV challenge which induced immunopathology
in animals with persistent viremia, the 3 animals with transient
viremia continued to have lymphocyte phenotypic values and
clinical observations that were indistinguishable from those of
uninfected animals for an additional year of observation. The ex-
istence of the CCR5-32 allele in human population gives some
clues as to the potential side effects of anti-CCR5 therapy. To date,
the only suggestion that the CCR5-32 mutation may be associ-
ated with enhanced susceptibility to disease is in individuals in-
fected with two flaviviruses, West Nile Virus and tickborne en-
cephalitis virus (57, 58). Nevertheless, the consequences of
functional inactivation of CCR5 in normal individuals cannot
necessarily be predicted by examination of knockout individuals.
Of significance to the current study, PRO 140 (Progenics Pharma-
ceuticals Inc.) is a humanized anti-CCR5 monoclonal antibody
(MAb) that is in clinical development for the treatment of HIV
infection. In a phase 2a study, PRO 140 was found to be well
tolerated and, at the highest dose, provided a mean viral load
reduction of 1.65 log (12). Similarly, HGS004, a fully humanized
IgG4 monoclonal antibody, was found to be safe and, at the higher
doses, gave a 1 log reduction in plasma HIV RNA levels in 54%
of study subjects (59). If a favorable safety profile of these and
later-generation antibodies emerges from larger phase 3 clinical
trials, it would support the possibility that a CCR5 antibody-in-
ducing vaccine could also be safely delivered. The cost of delivery
would clearly favor a CCR5 vaccine over administration of anti-
CCR5 MAb for use in the developing world. The development of
such a vaccine also needs to address whether, if infection is not
prevented, it would select for viral variants that use alternative
coreceptors (such as CXCR4) as is observed upon treatment with
maraviroc (60).
Because CCR5-specific antibodies are likely to be most effec-
tive at reducing viral infection and replication when also present at
the initial site of viral entry, this experiment included two CCR5
vaccine arms. While the IM group received exclusively intramus-
cular immunizations, the IM/VAG group, after an initial intra-
muscular immunization (to induce systemic antibodies), received
intravaginal booster immunizations also. In mice, a similar intra-
vaginal aerosol immunization strategy had previously been found
to induce IgG levels in the genital tract similar to those induced by
the intramuscular immunization route (47). In the current non-
human primate study, although the IM group developed slightly
higher anti-CCR5 antibody titers in plasma than the IM/VAG
group, we were not able to evaluate mucosal antibody levels, and
there was no clear distinction between the outcomes after the vag-
inal SIVmac251 challenge, probably due to the small group sizes.
Accordingly, for the remainder of this discussion, the data from
the two groups are combined without further distinction.
The two CCR5 peptide vaccine constructs used in the current
study were clearly immunogenic, as high titers of peptide-specific
antibodies in plasma of both immunization groups (IM and IM/
VAG) could be detected by ELISA methods. However, an in vitro
viral inhibition assay, adapted from an established neutralization
assay performed with TZM-bl cells, failed to detect significant
inhibitory activity. Reasons for this can be multiple. It is unclear
whether the anti-rhesus CCR5 antibodies cross-react with human
CCR5 on TZM-bl cells; in this context, the 2D7 antibody recog-
nizes human CCR5 (61) but not macaque CCR5 due to a single
K-to-R change in this domain (62). In addition, as the level of
CCR5 expression on TZM-bl cells is approximately 10-to-100-
fold higher than on PBMC (48), this creates a higher barrier for in
vitro inhibition and thus may lead to underestimation of the po-
tential antiviral activity in vivo. However, in vitro viral inhibition
assays that use primary rhesus PBMC are cumbersome and
plagued by high variability. Thus, a novel assay(s) using macaque
target cells may need to be developed to more closely mimic the
antiviral activity of macaque anti-CCR5 antibody in vivo.
Following immunization, all animals were exposed intravagi-
nally to a high dose of the very virulent SIVmac251 isolate. This
challenge model is predicted to establish persistent viremia in
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nearly 100% of control animals. While the control animals and the
majority of CCR5-immunized animals had the typical course of
SIVmac251 infection with persistent viremia that correlated with
disease progression, three immunized animals had a very unusual
course of infection. These 3 animals showed an initial transient
viremia (with detectable viral RNA at 4 consecutive time points)
which after week 4 became undetectable.
We were not able to identify a clear correlate of protection for
these 3 animals based on immunologic markers in peripheral
blood. On the day of SIV challenge, the anti-CCR5 antibody titers
in plasma of these 3 animals were in the higher range of their
groups. Their preinfection CCR5 expression levels on peripheral
blood lymphocytes were indistinguishable from those of the other
animals. However, a limitation of our study is that we were not
able to assess anti-CCR5 antibody levels and CCR5 receptor oc-
cupancy in the vaginal mucosa, where infection would have been
initiated, or in the draining lymph nodes that facilitate viral dis-
semination.
The peak levels (103 to 104 SIV copies/ml plasma) and dura-
tion of the transient viremia in these 3 animals were indistinguish-
able from those observed following infection with some attenu-
ated SIVs, such as the avirulent molecular clone SIVmac1A11.
However, an important distinction is that SIVmac1A11-infected
animals make SIV-specific antibodies within a few weeks of infec-
tion (63–65), while in the current study, the 3 protected animals
did not mount any detectable anti-SIV antibody response. The
lack of seroconversion, the undetectable virus levels in lymph
node and colon biopsy specimens, the inability of the CD8 de-
pletion experiment to induce a viral rebound or seroconversion,
and the high primary viremia upon stringent rechallenge suggest
that the infection might have been cleared (i.e., might have been
an abortive infection), rather than being a persistent, lingering
infection of the kind associated with sustained antiviral immune
responses. Similar observations suggestive of abortive infection
have previously been described in preexposure prophylaxis stud-
ies where some drug-treated macaques exposed mucosally to SIV-
mac251 resulted in transient detection of low viremia and/or low
antiviral antibody responses but afterward became negative by all
markers, including no evidence of antiviral immunity upon re-
challenge (66, 67). As hypothesized previously (66, 67), this phe-
nomenon may be due to the many replication-defective or repli-
cation-impaired viral variants that are present in the uncloned
SIVmac251 stocks, because in a high-dose challenge model, even
minor variants are given the opportunity to initiate mucosal in-
fection. Similar to the results seen with other in vitro-grown virus
stocks, the amount of viral RNA greatly exceeds the levels of rep-
lication-competent virions, which suggests that most viral RNA
copies represent noninfectious virus particles or infectious virus
particles with defective genomes that, upon infection of target
cells, can still induce a transient release of viral RNA into the
circulation but cannot disseminate and establish persistent infec-
tion. In this context, we hypothesize that in the 3 protected ani-
mals in the current study, the anti-CCR5 antibodies reduced the
effective infectious dose of the high-dose inoculum to below the
threshold needed to establish a classical persistent infection.
Although the protective effect of the CCR5 vaccine constructs
in the current study was limited to 3 of the 12 immunized animals
(25%), it should be noted that we used a high-dose viral challenge
model. As explained elsewhere, repeated low-dose viral challenge
models are biologically very relevant and may be more relevant
than high-dose challenge models to detect the protective effects of
prophylactic strategies, as efficacy may be missed or underesti-
mated with high-dose inoculation models (68). Accordingly, fu-
ture studies aimed at further improving anti-CCR5 vaccines in
nonhuman primate models can be performed best in such re-
peated low-dose challenge models that have been developed for
every mucosal route.
More than 1 year after the initial SIVmac251 inoculation, the 3
animals were reexposed to an increasingly stringent SIVmac251
challenge by first the intravaginal and then the intravenous route
of inoculation. Because all 3 animals became infected, this indi-
cates that the resistance to infection induced by the CCR5 vaccine
was, as expected, relative and became weaker when anti-CCR5
antibody numbers declined, especially against an intravenous
high-dose challenge.
In conclusion, although the efficacy of the current vaccine con-
structs in a high-dose viral challenge model was only moderate,
the data of our study offer a promising step forward and provide
support for further research into anti-CCR5-targeting vaccines to
reduce HIV transmission and replication. In particular, future
research can focus on optimizing vaccine constructs, adjuvants,
and immunization regimens to induce high-quality antibody re-
sponses that are durable and effective in blocking SIV and HIV
infection at the sites of mucosal transmission and preventing sys-
temic dissemination.
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